MBGN.F Stock Overview
Does not have significant operations. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Many Bright Ideas Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.01 |
| 52 Week High | CA$0.011 |
| 52 Week Low | CA$0.0062 |
| Beta | 0.41 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -88.89% |
| 5 Year Change | -82.54% |
| Change since IPO | -93.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| MBGN.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 1.6% |
| 1Y | n/a | 18.8% | 32.3% |
Return vs Industry: Insufficient data to determine how MBGN.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MBGN.F performed against the US Market.
Price Volatility
| MBGN.F volatility | |
|---|---|
| MBGN.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MBGN.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MBGN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Iain Weir-Jones | www.medbiogene.com |
Many Bright Ideas Technologies Inc. does not have significant operations. It was previously engaged in the life science business with a focus on the commercialization of prognostic genomic-based tests for non-small-cell lung cancer. It focuses on the commercialization of technologies in various industrial sectors.
Many Bright Ideas Technologies Inc. Fundamentals Summary
| MBGN.F fundamental statistics | |
|---|---|
| Market cap | US$252.43k |
| Earnings (TTM) | -US$56.96k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.4x
P/E RatioIs MBGN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBGN.F income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$56.96k |
| Earnings | -US$56.96k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0033 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MBGN.F perform over the long term?
See historical performance and comparison